Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cretostimogene grenadenorepvec - CG Oncology

Next Previous
Drug Profile

Cretostimogene grenadenorepvec - CG Oncology

Alternative Names: CG-0070

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer CG Oncolgy; Lepu Biopharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer
  • No development reported Solid tumours

Most Recent Events

  • 27 Feb 2026 CG Oncology expects to complete rolling BLA submission for Bladder cancer (Second-line therapy or greater, Monotherapy) in 2026
  • 09 Dec 2025 Efficacy and adverse events data from the cohort A of the phase II CORE-008 trial in Bladder cancer released by CG Oncology
  • 05 Dec 2025 Updated efficacy and adverse events data from the cohort P of the phase III BOND-003 trial in Bladder cancer released by CG Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top